{"entity":{"id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","aka":[],"tldr":"JNJ-79635322 is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for multiple myeloma, with its target not yet stated publicly.","summary":"JNJ-79635322 is an investigational agent whose form is not stated in the registry developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: JNJ-79635322 will be administered as SC injection. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07258511 (A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma) and NCT07518186 (A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma), in multiple myeloma. The largest, NCT07518186, plans to enrol 700 participants with primary completion expected 2029-04-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of JNJ-79635322","url":"https://clinicaltrials.gov/search?intr=JNJ-79635322"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07258511","nct07518186","nct07266441","nct07589634"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"trispecific antibody (BCMA x GPRC5D x CD3, per the sponsor's pipeline page; form not stated in the registry record)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jnj-79635322/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"trial":[{"id":"nct07258511","kind":"trial","name":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07258511/"},{"id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07518186/"},{"id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","route":"/trials/nct07589634/"},{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/"}]}}